The decision to request a DXA scan in certain special situations (e.g., chronic liver disease, post- and pre-transplant solid or hematological malignancy, breast cancer, patients on aromatase inhibitors, patients on androgen ablation therapy, etc.)depends on the treating physician and can be considered in these special cases. Here, CYP19A1 is linked to breast cancer.